Idera Pharmaceuticals is focused on applying its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The company has clinical development programs in autoimmune diseases and cancer and also has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. Idera is additionally developing its gene-silencing oligonucleotide technology for inhibiting the expression of disease-promoting genes. For more information, visit the company’s Web site at www.iderapharma.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: